GraceFinance · Source-backed public company research

Viridian Therapeutics, Inc.\DE (VRDN)

Nasdaq · Manufacturing · Pharmaceutical Preparations

Core research established · 4/4 core data layers currently established

What Viridian Therapeutics, Inc.\DE does

Company Overview We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients. We aim to develop differentiated, potential best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, and expanded market access. Our pipeline targets validated pathways and disease-driving mechanisms in autoimmune and rare diseases.

Verify the company description in the original SEC filing

Open the company story

The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.